ATAI
Trust-weighted public proof page for ATAI. See which authors support it, which ticker theses it belongs to, and how thesis calls have performed.
Recent proof-backed thesis calls
Public preview of asset-level thesis calls linked to source content, observed prices, and outcomes.
Report says Eli Lilly (LLY) is acquiring psychedelic drugmaker AtaiBeckley for $3.8B, gaining exposure to a late-stage-ish psychedelic-derived intranasal candidate (BPL-003, DMT-derivative) for treatment-resistant depression (TRD). Mentions existing TRD product Spravato (esketamine) from Johnson & Johnson (JNJ) as context/benchmark. Actionability is moderate: clear M&A catalyst for the target and read-through for the psychiatric/psychedelic therapeutics space, but key details (deal terms, premiu
Current stance
- beneficiary via M&A validation trade in psychedelic/TRD therapeutics from https://www.youtube.com/channel/UCIALMKvObZNtJ6AmdCLP7Lg (confidence 0.46)
Top authors on this asset
Active and historical ticker theses
Unlock full asset monitoring
Create an account to access full asset history, alerts, Telegram workflows, and trust-weighted live rankings across authors, ticker theses, and market events.